156 related articles for article (PubMed ID: 38325605)
1. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
[TBL] [Abstract][Full Text] [Related]
2. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
Cutler AJ; Mattingly GW; Kornstein SG; Aaronson ST; Lasser R; Zhang H; Rana N; Brown C; Levin S; Miller C; Kotecha M; Forrestal F; Doherty J
J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38153320
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
[TBL] [Abstract][Full Text] [Related]
7. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Clayton AH; Lasser R; Nandy I; Sankoh AJ; Jonas J; Kanes SJ
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36811520
[No Abstract] [Full Text] [Related]
8. Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
[TBL] [Abstract][Full Text] [Related]
10. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
[No Abstract] [Full Text] [Related]
11. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
[TBL] [Abstract][Full Text] [Related]
12. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
Winslow M; White E; Rose SJ; Salzer E; Nemec EC
Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
[TBL] [Abstract][Full Text] [Related]
15. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
[TBL] [Abstract][Full Text] [Related]
16. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
Kato M; Nakagome K; Baba T; Sonoyama T; Okutsu D; Yamanaka H; Shimizu R; Motomiya T; Inoue T
Psychiatry Clin Neurosci; 2023 Sep; 77(9):497-509. PubMed ID: 37252829
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
[TBL] [Abstract][Full Text] [Related]
20. Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials.
Lian J; Lin Z; Li X; Chen G; Wu D
J Affect Disord; 2024 Jun; 354():206-215. PubMed ID: 38479510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
